PURAPLY®AM SCIENTIFIC DATA

Discover the antimicrobial effectiveness of PuraPly AM in nonclinical studies.

PuraPly AM reduced concentrations of Aspergillus niger, MRSA, Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli in wounds

  • >98% reduction of MRSA counts compared to baseline
  • >96% reduction of MRSA counts vs untreated control on all assessment days
  • Largest reduction of MRSA counts vs any of the other treatment groups
  • The only treatment to substantially reduce MRSA within 2 days

Watch principal investigator Stephen C. Davis discuss the details of the preliminary study.

SUPPORTING WOUND CLOSURE IN REAL-WORLD STUDIES

See how PuraPly AM supported healing in real-world studies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.

Contact us

REFERENCES:

  1. Data on file. USP Antimicrobial Effectiveness Test. Organogenesis Inc.
  2. Data on file. PDR-0001. Organogenesis Inc.